{"title":"Personalized T cell-mediated cancer immunotherapy: progress and challenges","uri":"","abstract":"Immunotherapies are yielding effective treatments for several previously untreatable cancers. Until recently, vaccines and adoptive cell therapies have been designed to target public tumor antigens common to multiple patients rather than private antigens specific to a single patient. Due to the difficulty of identifying public antigens that are expressed exclusively on tumor cells, these studies have yielded both clinical successes and serious immune-related adverse events. Multiple avenues of research now underscore the centrality of tumor-specific mutated private antigens to endogenous anti-tumor immunity. Immunotherapies that target these neoantigens may enable safer and more durable tumor regression, but personalized targeting presents a number of challenges. Foremost among these is to develop processes that accelerate advancement from neoantigen discovery to use of these neoantigens as vaccines or as targets for adoptive cell therapies. Exome sequencing has facilitated discovery of neoantigens for melanoma and other highly mutated cancers. New technologies – possibly proceeding from T cell receptor repertoire sequencing – are needed to identify antigens for cancers with low mutational burden and few neoantigens. In this review, we discuss progress toward personalizing T cell-mediated immunotherapy for cancer as well as challenges going forward.","documents":[{"id":"http://authors.library.caltech.edu/id/document/251955","docid":251955,"rev_number":2,"files":[{"id":"http://authors.library.caltech.edu/id/file/1255535","fileid":1255535,"datasetid":"document","objectid":251955,"filename":"1-s2.0-S095816691630283X-main.pdf","mime_type":"application/pdf","hash":"7f47c0a4a27ed5bcb9f6d36eeca7c161","hash_type":"MD5","filesize":935241,"mtime":"2017-05-09 16:57:43","url":"http://authors.library.caltech.edu/77294/1/1-s2.0-S095816691630283X-main.pdf"}],"eprintid":77294,"pos":1,"placement":1,"mime_type":"application/pdf","format":"application/pdf","language":"en","security":"public","license":"cc_by_nc_nd","main":"1-s2.0-S095816691630283X-main.pdf","content":"published"}],"note":"© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/). \n\nAvailable online 8 May 2017. \n\nWe thank David Baltimore, Owen Witte, Antoni Ribas, Christopher Seet, Eric Gschweng, Jocelyn Kim, Arnav Mehta, Stephanie Wong, and Donald Kohn for their critiques of the manuscript. M.T.B. is supported by the Prostate Cancer Foundation Challenge award 15CHAL02 and the Parker Institute for Cancer Immunotherapy. A.V.J. is supported by the Caltech Innovation Initiative (CI2) award and the California Institute of Regenerative Medicine award DISC2-09123.","id":77294,"rev_number":6,"userid":18,"eprint_dir":"disk0/00/07/72/94","datestamp":"2017-05-12 22:30:37","lastmod":"2017-05-12 22:30:37","status_changed":"2017-05-12 22:30:37","type":"article","metadata_visibility":"show","creators":[{"given":"Michael T.","family":"Bethune","id":"Bethune-M-T","orcid":""},{"given":"Alok V.","family":"Joglekar","id":"Joglekar-A-V","orcid":""}],"ispublished":"pub","subjects":null,"full_text_status":"public","keywords":"","date":"2017-12","date_type":"published","publication":"Current Opinion in Biotechnology","volume":"48","number":"","pagerange":"142-152","id_number":"CaltechAUTHORS:20170509-095739381","refereed":true,"issn":"0958-1669 ","official_url":"http://resolver.caltech.edu/CaltechAUTHORS:20170509-095739381","related_url":[{"url":"https://doi.org/10.1016/j.copbio.2017.03.024","type":"doi","description":"Article"},{"url":"http://www.sciencedirect.com/science/article/pii/S095816691630283X","type":"pub","description":"Article"}],"referencetext":["1\nR.T. Prehn, J.M. Main\n\nImmunity to methylcholanthrene-induced sarcomas\n\n\nJ. Natl. Cancer Inst., 18 (1957), pp. 769–778\n\nView Record in Scopus | Citing articles (772)\n\n2\nL.J. Old, E.A. Boyse\n\nImmunology of experimental tumors\n\n\nAnnu. Rev. Med., 15 (1964), pp. 167–186\n\nCrossRef | View Record in Scopus | Citing articles (244)\n\n3\nM. Burnet\n\nCancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications\n\n\nBr. Med. J., 1 (1957), pp. 841–847\n\nCrossRef | View Record in Scopus | Citing articles (200)\n\n4\nM.M. Black, S.R. Opler, F.D. Speer\n\nMicroscopic structure of gastric carcinomas and their regional lymph nodes in relation to survival\n\n\nSurg. Gynecol. Obstet., 98 (1954), pp. 725–734\n\nView Record in Scopus | Citing articles (66)\n\n5\nS.A. Rosenberg, J.C. Yang, N.P. Restifo\n\nCancer immunotherapy: moving beyond current vaccines\n\n\nNat. Med., 10 (2004), pp. 909–915\n\nCrossRef | View Record in Scopus | Citing articles (1861)\n\n6••\nV. Shankaran, H. Ikeda, A.T. Bruce, J.M. White, P.E. Swanson, L.J. Old, R.D. Schreiber\n\nIFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity\n\n\nNature, 410 (2001), pp. 1107–1111\n\nCrossRef | View Record in Scopus | Citing articles (1338)\n\n\nIn addition to demonstrating that lymphocytes protect against carcinogen-induced and spontaneous cancers, this study showed that tumors from immunocompetent mice have reduced immunogenicity relative to those from immunocompromised (RAG2−/−) mice. Thus, the immune system not only protects the host from cancer (immunosurveillance) but also exerts selective pressure that sculpts the antigenic character of the developing tumor (immunoediting).\n\n\n\n7\nM.J. Smyth, K.Y. Thia, S.E. Street, D. MacGregor, D.I. Godfrey, J.A. Trapani\n\nPerforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma\n\n\nJ. Exp. Med., 192 (2000), pp. 755–760\n\nCrossRef | View Record in Scopus | Citing articles (332)\n\n8\nS.A. Rosenberg, M.T. Lotze, L.M. Muul, S. Leitman, A.E. Chang, S.E. Ettinghausen, Y.L. Matory, J.M. Skibber, E. Shiloni, J.T. Vetto, et al.\n\nObservations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer\n\n\nN. Engl. J. Med., 313 (1985), pp. 1485–1492\n\nCrossRef | View Record in Scopus | Citing articles (1761)\n\n9\nM.T. Lotze, A.E. Chang, C.A. Seipp, C. Simpson, J.T. Vetto, S.A. Rosenberg\n\nHigh-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings\n\n\nJAMA, 256 (1986), pp. 3117–3124\n\nCrossRef | View Record in Scopus | Citing articles (323)\n\n10\nS.A. Rosenberg, B.S. Packard, P.M. Aebersold, D. Solomon, S.L. Topalian, S.T. Toy, P. Simon, M.T. Lotze, J.C. Yang, C.A. Seipp, et al.\n\nUse of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report\n\n\nN. Engl. J. Med., 319 (1988), pp. 1676–1680\n\nCrossRef | View Record in Scopus | Citing articles (1251)\n\n11\nM.E. Dudley, J.R. Wunderlich, P.F. Robbins, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R. Sherry, N.P. Restifo, A.M. Hubicki, et al.\n\nCancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes\n\n\nScience, 298 (2002), pp. 850–854\n\nCrossRef | View Record in Scopus | Citing articles (1869)\n\n12•\nC. Yee, J.A. Thompson, D. Byrd, S.R. Riddell, P. Roche, E. Celis, P.D. Greenberg\n\nAdoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells\n\n\nProc. Natl. Acad. Sci. U. S. A., 99 (2002), pp. 16168–16173\n\nCrossRef | View Record in Scopus | Citing articles (816)\n\n\nThis study and Dudley  et al. (Ref. [11]) established that clonal adoptive T cell therapy (using clones reactive with MART1 and/or gp100) can cause tumor regression in patients with metastatic melanoma, laying the groundwork for tailored adoptive TIL therapy with neoantigen-specific TILs.\n\n\n\n13\nD.R. Leach, M.F. Krummel, J.P. Allison\n\nEnhancement of antitumor immunity by CTLA-4 blockade\n\n\nScience, 271 (1996), pp. 1734–1736\n\nView Record in Scopus | Citing articles (1307)\n\n14\nF.S. Hodi, S.J. O’Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J.C. Hassel, et al.\n\nImproved survival with ipilimumab in patients with metastatic melanoma\n\n\nN. Engl. J. Med., 363 (2010), pp. 711–723\n\nCrossRef | View Record in Scopus | Citing articles (5146)\n\n15•\nS.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, R.D. Carvajal, J.A. Sosman, M.B. Atkins, et al.\n\nSafety, activity, and immune correlates of anti-PD-1 antibody in cancer\n\n\nN. Engl. J. Med., 366 (2012), pp. 2443–2454\n\nCrossRef | View Record in Scopus | Citing articles (3591)\n\n\nThis study illustrated that checkpoint (PD-1) blockade can mobilize anti-tumor immunity for several cancers with high mutational burden. Response was achieved in patients with melanoma (28%), renal cell cancer (27%), and non-small-cell lung cancer (18%). These responses were durable (\u003e1 year in 20/31 responders) and were associated with PD-L1 expression on the tumor cells. Notably, no responses were seen among patients with prostate cancer, which has a generally low mutational burden.\n\n\n\n16\nJ. Couzin-Frankel\n\nBreakthrough of the year 2013. Cancer immunotherapy\n\n\nScience, 342 (2013), pp. 1432–1433\n\nCrossRef | View Record in Scopus | Citing articles (406)\n\n17\nT. Boon, P. van der Bruggen\n\nHuman tumor antigens recognized by T lymphocytes\n\n\nJ. Exp. Med., 183 (1996), pp. 725–729\n\nCrossRef | View Record in Scopus | Citing articles (711)\n\n\n\n\n18\nM.M. Gubin, M.N. Artyomov, E.R. Mardis, R.D. Schreiber\n\nTumor neoantigens: building a framework for personalized cancer immunotherapy\n\n\nJ. Clin. Invest., 125 (2015), pp. 3413–3421\n\nCrossRef | View Record in Scopus | Citing articles (34)\n\n19\nA. Anichini, C. Maccalli, R. Mortarini, S. Salvi, A. Mazzocchi, P. Squarcina, M. Herlyn, G. Parmiani\n\nMelanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients\n\n\nJ. Exp. Med., 177 (1993), pp. 989–998\n\nCrossRef | View Record in Scopus | Citing articles (137)\n\n20\nP.W. Kantoff, C.S. Higano, N.D. Shore, E.R. Berger, E.J. Small, D.F. Penson, C.H. Redfern, A.C. Ferrari, R. Dreicer, R.B. Sims, et al.\n\nSipuleucel-T immunotherapy for castration-resistant prostate cancer\n\n\nN. Engl. J. Med., 363 (2010), pp. 411–422\n\nCrossRef | View Record in Scopus | Citing articles (2352)\n\n21\nZ. Dembic, W. Haas, S. Weiss, J. McCubrey, H. Kiefer, H. von Boehmer, M. Steinmetz\n\nTransfer of specificity by murine alpha and beta T-cell receptor genes\n\n\nNature, 320 (1986), pp. 232–238\n\nCrossRef | View Record in Scopus | Citing articles (310)\n\n22\nL.A. Johnson, B. Heemskerk, D.J. Powell Jr., C.J. Cohen, R.A. Morgan, M.E. Dudley, P.F. Robbins, S.A. Rosenberg\n\nGene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes\n\n\nJ. Immunol., 177 (2006), pp. 6548–6559\n\nCrossRef | View Record in Scopus | Citing articles (162)\n\n23\nR.A. Morgan, M.E. Dudley, J.R. Wunderlich, M.S. Hughes, J.C. Yang, R.M. Sherry, R.E. Royal, S.L. Topalian, U.S. Kammula, N.P. Restifo, et al.\n\nCancer regression in patients after transfer of genetically engineered lymphocytes\n\n\nScience, 314 (2006), pp. 126–129\n\nCrossRef | View Record in Scopus | Citing articles (1458)\n\n24•\nL.A. Johnson, R.A. Morgan, M.E. Dudley, L. Cassard, J.C. Yang, M.S. Hughes, U.S. Kammula, R.E. Royal, R.M. Sherry, J.R. Wunderlich, et al.\n\nGene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen\n\n\nBlood, 114 (2009), pp. 535–546\n\nCrossRef | View Record in Scopus | Citing articles (618)\n\n\nThis study highlights the strengths and limitations of targeting public antigens with TCR gene therapy. Gene therapy using high affinity melanocyte antigen-specific TCRs achieved an objective response rate of 30% in patients with metastatic melanoma, but also resulted in morbidity (vitiligo, uveitis, and hearing loss) due to on-target, off-tumor reactivity.\n\n\n\n25\nP.F. Robbins, R.A. Morgan, S.A. Feldman, J.C. Yang, R.M. Sherry, M.E. Dudley, J.R. Wunderlich, A.V. Nahvi, L.J. Helman, C.L. Mackall, et al.\n\nTumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1\n\n\nJ. Clin. Oncol., 29 (2011), pp. 917–924\n\nCrossRef | View Record in Scopus | Citing articles (628)\n\n26\nP.F. Robbins, S.H. Kassim, T.L. Tran, J.S. Crystal, R.A. Morgan, S.A. Feldman, J.C. Yang, M.E. Dudley, J.R. Wunderlich, R.M. Sherry, et al.\n\nA pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response\n\n\nClin. Cancer Res., 21 (2015), pp. 1019–1027\n\nCrossRef | View Record in Scopus | Citing articles (89)\n\n27\n\nDo no harm\n\n\nNat. Biotechnol., 31 (2013), p. 365\n\n\n\n28\nG.P. Linette, E.A. Stadtmauer, M.V. Maus, A.P. Rapoport, B.L. Levine, L. Emery, L. Litzky, A. Bagg, B.M. Carreno, P.J. Cimino, et al.\n\nCardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma\n\n\nBlood, 122 (2013), pp. 863–871\n\nCrossRef | View Record in Scopus | Citing articles (265)\n\n29\nB.J. Cameron, A.B. Gerry, J. Dukes, J.V. Harper, V. Kannan, F.C. Bianchi, F. Grand, J.E. Brewer, M. Gupta, G. Plesa, et al.\n\nIdentification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells\n\n\nSci. Transl. Med., 5 (2013), p. 197ra103\n\nCrossRef\n\n30\nJ.H. van den Berg, R. Gomez-Eerland, B. van de Wiel, L. Hulshoff, D. van den Broek, A. Bins, H.L. Tan, J.V. Harper, N.J. Hassan, B.K. Jakobsen, et al.\n\nCase report of a fatal serious adverse event upon administration of T cells transduced with a MART-1-specific T-cell receptor\n\n\nMol. Ther., 23 (2015), pp. 1541–1550\n\nArticle |  PDF (1613 K) | CrossRef | View Record in Scopus | Citing articles (9)\n\n31\nT. Chodon, B. Comin-Anduix, B. Chmielowski, R.C. Koya, Z. Wu, M. Auerbach, C. Ng, E. Avramis, E. Seja, A. Villanueva, et al.\n\nAdoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma\n\n\nClin. Cancer Res., 20 (2014), pp. 2457–2465\n\nCrossRef | View Record in Scopus | Citing articles (35)\n\n32\nA.P. Rapoport, E.A. Stadtmauer, G.K. Binder-Scholl, O. Goloubeva, D.T. Vogl, S.F. Lacey, A.Z. Badros, A. Garfall, B. Weiss, J. Finklestein, et al.\n\nNY-ESO-1-specific TCR-engineered T. cells mediate sustained antigen-specific antitumor effects in myeloma\n\n\nNat. Med., 21 (2015), pp. 914–921\n\nCrossRef | View Record in Scopus | Citing articles (94)\n\n33\nR.A. Morgan, N. Chinnasamy, D. Abate-Daga, A. Gros, P.F. Robbins, Z. Zheng, M.E. Dudley, S.A. Feldman, J.C. Yang, R.M. Sherry, et al.\n\nCancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy\n\n\nJ. Immunother., 36 (2013), pp. 133–151\n\nCrossRef | View Record in Scopus | Citing articles (274)\n\n34••\nP.F. Robbins, Y.C. Lu, M. El-Gamil, Y.F. Li, C. Gross, J. Gartner, J.C. Lin, J.K. Teer, P. Cliften, E. Tycksen, et al.\n\nMining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells\n\n\nNat. Med., 19 (2013), pp. 747–752\n\nCrossRef | View Record in Scopus | Citing articles (347)\n\n\nThis study and van Rooij  et al. (Ref. [53]) were the first to employ exome-guided neoantigen discovery in a clinical setting, either following TIL therapy (Robbins) or checkpoint blockade (van Rooij). Importantly, both studies confirmed the presence of endogenous T cells reactive with these neoantigens.\n\n\n\n35\nS.A. Rosenberg, M.E. Dudley\n\nAdoptive cell therapy for the treatment of patients with metastatic melanoma\n\n\nCurr. Opin. Immunol., 21 (2009), pp. 233–240\n\nArticle |  PDF (2866 K) | View Record in Scopus\n\n\n\n\n36••\nE. Tran, S. Turcotte, A. Gros, P.F. Robbins, Y.C. Lu, M.E. Dudley, J.R. Wunderlich, R.P. Somerville, K. Hogan, C.S. Hinrichs, et al.\n\nCancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer\n\n\nScience, 344 (2014), pp. 641–645\n\nCrossRef | View Record in Scopus | Citing articles (335)\n\n\nThis case study used an exome-guided approach to identify a neoantigen-reactive CD4+ T cell clone at high frequency (25%) among TILs from a patient with cholangiocarcinoma. Infusion of a nearly homogeneous enrichment of this clone caused tumor regression. Thus, this study illustrated that TIL frequency is a presumptive indicator of neoantigen reactivity and clinical efficacy, and validated that tailored TIL therapy containing a single neoantigen-reactive clone can achieve tumor regression.\n\n\n\n37\nA. Snyder, V. Makarov, T. Merghoub, J. Yuan, J.M. Zaretsky, A. Desrichard, L.A. Walsh, M.A. Postow, P. Wong, T.S. Ho, et al.\n\nGenetic basis for clinical response to CTLA-4 blockade in melanoma\n\n\nN. Engl. J. Med., 371 (2014), pp. 2189–2199\n\nCrossRef | View Record in Scopus | Citing articles (760)\n\n38\nE.M. Van Allen, D. Miao, B. Schilling, S.A. Shukla, C. Blank, L. Zimmer, A. Sucker, U. Hillen, M.H. Geukes Foppen, S.M. Goldinger, et al.\n\nGenomic correlates of response to CTLA-4 blockade in metastatic melanoma\n\n\nScience, 350 (2015), pp. 207–211\n\nCrossRef | View Record in Scopus | Citing articles (239)\n\n39•\nN.A. Rizvi, M.D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J.J. Havel, W. Lee, J. Yuan, P. Wong, T.S. Ho, et al.\n\nCancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer\n\n\nScience, 348 (2015), pp. 124–128\n\nCrossRef | View Record in Scopus | Citing articles (866)\n\n\nThis study showed that a higher number of non-synonymous mutations and neoantigens in lunger cancer were associated with higher clinical benefit from antibody-mediated inhibition of PD-1. This supported the use of mutational burden as a prognostic biomarker for checkpoint blockade therapies.\n\n\n\n40\nD.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring, A.D. Skora, B.S. Luber, N.S. Azad, D. Laheru, et al.\n\nPD-1 blockade in tumors with mismatch-repair deficiency\n\n\nN. Engl. J. Med., 372 (2015), pp. 2509–2520\n\nCrossRef | View Record in Scopus | Citing articles (883)\n\n41\nN. McGranahan, A.J. Furness, R. Rosenthal, S. Ramskov, R. Lyngaa, S.K. Saini, M. Jamal-Hanjani, G.A. Wilson, N.J. Birkbak, C.T. Hiley, et al.\n\nClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade\n\n\nScience, 351 (2016), pp. 1463–1469\n\nCrossRef | View Record in Scopus | Citing articles (179)\n\n42\nK.E. Pauken, M.A. Sammons, P.M. Odorizzi, S. Manne, J. Godec, O. Khan, A.M. Drake, Z. Chen, D.R. Sen, M. Kurachi, et al.\n\nEpigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade\n\n\nScience, 354 (2016), pp. 1160–1165\n\nCrossRef | View Record in Scopus | Citing articles (13)\n\n43\nM.A. Postow, J. Chesney, A.C. Pavlick, C. Robert, K. Grossmann, D. McDermott, G.P. Linette, N. Meyer, J.K. Giguere, S.S. Agarwala, et al.\n\nNivolumab and ipilimumab versus ipilimumab in untreated melanoma\n\n\nN. Engl. J. Med., 372 (2015), pp. 2006–2017\n\nCrossRef | View Record in Scopus | Citing articles (558)\n\n44\nT.N. Schumacher, R.D. Schreiber\n\nNeoantigens in cancer immunotherapy\n\n\nScience, 348 (2015), pp. 69–74\n\nCrossRef | View Record in Scopus | Citing articles (418)\n\n45•\nC. Linnemann, M.M. van Buuren, L. Bies, E.M. Verdegaal, R. Schotte, J.J. Calis, S. Behjati, A. Velds, H. Hilkmann, D.E. Atmioui, et al.\n\nHigh-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma\n\n\nNat. Med., 21 (2015), pp. 81–85\n\nView Record in Scopus | Citing articles (101)\n\n\nThis study demonstrated that endogenous anti-tumor immune responses directed at both MHC class I- and MHC class II-restricted neoantigens are common in patients with melanoma.\n\n\n\n46\nE. Tran, M. Ahmadzadeh, Y.C. Lu, A. Gros, S. Turcotte, P.F. Robbins, J.J. Gartner, Z. Zheng, Y.F. Li, S. Ray, et al.\n\nImmunogenicity of somatic mutations in human gastrointestinal cancers\n\n\nScience, 350 (2015), pp. 1387–1390\n\nCrossRef | View Record in Scopus | Citing articles (81)\n\n47•\nE. De Plaen, C. Lurquin, A. Van Pel, B. Mariame, J.P. Szikora, T. Wolfel, C. Sibille, P. Chomez, T. Boon\n\nImmunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation\n\n\nProc. Natl. Acad. Sci. U. S. A., 85 (1988), pp. 2274–2278\n\nCrossRef | View Record in Scopus | Citing articles (144)\n\n\nThis study identified a point mutation responsible for rejection of an immunogenic tumor in syngeneic mice. This study provided the first molecular evidence that the immune system can reject cancers based on mutated antigens. It also established an expression cloning approach that was subsequently used to clone other (non-mutated) tumor rejection antigens.\n\n\n\n48\nM. Nielsen, C. Lundegaard, P. Worning, S.L. Lauemoller, K. Lamberth, S. Buus, S. Brunak, O. Lund\n\nReliable prediction of T-cell epitopes using neural networks with novel sequence representations\n\n\nProtein Sci., 12 (2003), pp. 1007–1017\n\nCrossRef | View Record in Scopus | Citing articles (356)\n\n49\nM. Andreatta, M. Nielsen\n\nGapped sequence alignment using artificial neural networks: application to the MHC class I system\n\n\nBioinformatics, 32 (2016), pp. 511–517\n\nCrossRef\n\n50\nN.H. Segal, D.W. Parsons, K.S. Peggs, V. Velculescu, K.W. Kinzler, B. Vogelstein, J.P. Allison\n\nEpitope landscape in breast and colorectal cancer\n\n\nCancer Res., 68 (2008), pp. 889–892\n\nCrossRef | View Record in Scopus | Citing articles (190)\n\n51\nH. Matsushita, M.D. Vesely, D.C. Koboldt, C.G. Rickert, R. Uppaluri, V.J. Magrini, C.D. Arthur, J.M. White, Y.S. Chen, L.K. Shea, et al.\n\nCancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting\n\n\nNature, 482 (2012), pp. 400–404\n\nCrossRef | View Record in Scopus | Citing articles (362)\n\n\n\n\n52•\nJ.C. Castle, S. Kreiter, J. Diekmann, M. Lower, N. van de Roemer, J. de Graaf, A. Selmi, M. Diken, S. Boegel, C. Paret, et al.\n\nExploiting the mutanome for tumor vaccination\n\n\nCancer Res., 72 (2012), pp. 1081–1091\n\n\n\n\nThis study and Matsushita  et al. (Ref. [51]) used exome sequencing and predictive MHC binding algorithms to identify neoantigens in mouse models. Detection of neoantigen-reactive T cells in these mice provided direct evidence of endogenous immune recognition of neoantigens and validated this exome-guided approach for neoantigen discovery.\n\n\n\n53\nN. van Rooij, M.M. van Buuren, D. Philips, A. Velds, M. Toebes, B. Heemskerk, L.J. van Dijk, S. Behjati, H. Hilkmann, D. El Atmioui, et al.\n\nTumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma\n\n\nJ. Clin. Oncol., 31 (2013), pp. e439–e442\n\n\n\n54•\nM.M. Gubin, X. Zhang, H. Schuster, E. Caron, J.P. Ward, T. Noguchi, Y. Ivanova, J. Hundal, C.D. Arthur, W.J. Krebber, et al.\n\nCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens\n\n\nNature, 515 (2014), pp. 577–581\n\n\n\n\nThis study supports the promise of personalized therapeutic vaccination by showing that immunization of mice with neoantigen-derived peptides can elicit rejection of sarcomas. Subsequent application of this approach in patients with advanced melanoma stimulated expansion of neoantigen-reactive clones, although without clinical benefit (Carreno  et al., Ref. [56]).\n\n\n\n55\nM. Yadav, S. Jhunjhunwala, Q.T. Phung, P. Lupardus, J. Tanguay, S. Bumbaca, C. Franci, T.K. Cheung, J. Fritsche, T. Weinschenk, et al.\n\nPredicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing\n\n\nNature, 515 (2014), pp. 572–576\n\n\n\n56\nB.M. Carreno, V. Magrini, M. Becker-Hapak, S. Kaabinejadian, J. Hundal, A.A. Petti, A. Ly, W.R. Lie, W.H. Hildebrand, E.R. Mardis, et al.\n\nCancer immunotherapy: a dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells\n\n\nScience, 348 (2015), pp. 803–808\n\n\n\n57••\nM. Bassani-Sternberg, E. Braunlein, R. Klar, T. Engleitner, P. Sinitcyn, S. Audehm, M. Straub, J. Weber, J. Slotta-Huspenina, K. Specht, et al.\n\nDirect identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry\n\n\nNat. Commun., 7 (2016), p. 13404\n\n\n\n\nThis study directly uses a powerful workflow of peptide elution from human tumors (melanoma), mass spectrometry, and comparison to exome sequencing to identify 95 500 patient-presented peptides, including mutated and phosphorylated ligands. Importantly, many of the ligands identified would have been excluded based on low predicted affinity for MHC using MHC binding algorithms.\n\n\n\n58\nJ. Petersen, S.J. Wurzbacher, N.A. Williamson, S.H. Ramarathinam, H.H. Reid, A.K. Nair, A.Y. Zhao, R. Nastovska, G. Rudge, J. Rossjohn, et al.\n\nPhosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes\n\n\nProc. Natl. Acad. Sci. U. S. A., 106 (2009), pp. 2776–2781\n\n\n\n59\nM. Cobbold, H. De La Pena, A. Norris, J.M. Polefrone, J. Qian, A.M. English, K.L. Cummings, S. Penny, J.E. Turner, J. Cottine, et al.\n\nMHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia\n\n\nSci. Transl. Med., 5 (2013), p. 203ra125\n\n\n\n60\nM. Toebes, M. Coccoris, A. Bins, B. Rodenko, R. Gomez, N.J. Nieuwkoop, W. van de Kasteele, G.F. Rimmelzwaan, J.B. Haanen, H. Ovaa, et al.\n\nDesign and use of conditional MHC class I ligands\n\n\nNat. Med., 12 (2006), pp. 246–251\n\n\n\n61\nS.R. Hadrup, A.H. Bakker, C.J. Shu, R.S. Andersen, J. van Veluw, P. Hombrink, E. Castermans, P. Thor Straten, C. Blank, J.B. Haanen, et al.\n\nParallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers\n\n\nNat. Methods, 6 (2009), pp. 520–526\n\n\n\n62\nC.J. Cohen, J.J. Gartner, M. Horovitz-Fried, K. Shamalov, K. Trebska-McGowan, V.V. Bliskovsky, M.R. Parkhurst, C. Ankri, T.D. Prickett, J.S. Crystal, et al.\n\nIsolation of neoantigen-specific T cells from tumor and peripheral lymphocytes\n\n\nJ. Clin. Invest., 125 (2015), pp. 3981–3991\n\n\n\n63\nG.A. Kwong, C.G. Radu, K. Hwang, C.J. Shu, C. Ma, R.C. Koya, B. Comin-Anduix, S.R. Hadrup, R.C. Bailey, O.N. Witte, et al.\n\nModular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells\n\n\nJ. Am. Chem. Soc., 131 (2009), pp. 9695–9703\n\n\n\n64\nY.C. Lu, X. Yao, J.S. Crystal, Y.F. Li, M. El-Gamil, C. Gross, L. Davis, M.E. Dudley, J.C. Yang, Y. Samuels, et al.\n\nEfficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions\n\n\nClin. Cancer Res., 20 (2014), pp. 3401–3410\n\n\n\n65••\nA. Gros, M.R. Parkhurst, E. Tran, A. Pasetto, P.F. Robbins, S. Ilyas, T.D. Prickett, J.J. Gartner, J.S. Crystal, I.M. Roberts, et al.\n\nProspective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients\n\n\nNat. Med., 22 (2016), pp. 433–438\n\n\n\n\nThis paper demonstrates that most neoantigen specificities present among TILs can also be detected among peripheral T cells following expansion with neoantigen-expressing autologous presenting cells. This finding suggests adoptive T cell therapies may be feasible even when TILs cannot be obtained.\n\n\n\n66\nS.A. Rosenberg, J.C. Yang, R.M. Sherry, U.S. Kammula, M.S. Hughes, G.Q. Phan, D.E. Citrin, N.P. Restifo, P.F. Robbins, J.R. Wunderlich, et al.\n\nDurable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy\n\n\nClin. Cancer Res., 17 (2011), pp. 4550–4557\n\n\n\n67\nS. Kelderman, B. Heemskerk, L. Fanchi, D. Philips, M. Toebes, P. Kvistborg, M.M. van Buuren, N. van Rooij, S. Michels, L. Germeroth, et al.\n\nAntigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy\n\n\nEur. J. Immunol., 46 (2016), pp. 1351–1360\n\n\n\n\n\n\n68••\nE. Tran, P.F. Robbins, Y.-C. Lu, T.D. Prickett, J.J. Gartner, L. Jia, A. Pasetto, Z. Zheng, S. Ray, E.M. Groh, et al.\n\nT-cell transfer therapy targeting mutant KRAS in cancer\n\n\nN. Engl. J. Med., 375 (2016), pp. 2255–2262\n\n\n\n\nThis study employed adoptive TIL therapy against a relatively rare target: a neoantigen-forming mutation (KRAS G12D) that is also a driver of neoplastic growth. A patient with metastatic colorectal cancer was infused with autologous TILs containing 3 mutant KRAS-reactive TIL clonotypes collectively constituting \u003e75% of the TIL repertoire. Initially all metastases regressed. However, despite retention of the targeted driver mutation, one of the lesions evaded immunity through loss of expression of the presenting MHC molecule. Thus, this study proposes that driver mutations can be targeted via T cell immunity in a small subset of patients but also highlights the challenge posed by tumor immune evasion.\n\n\n\n69••\nA. Pasetto, A. Gros, P.F. Robbins, D.C. Deniger, T.D. Prickett, R. Matus-Nicodemos, D.C. Douek, B. Howie, H. Robins, M.R. Parkhurst, et al.\n\nTumor- and neoantigen-reactive t-cell receptors can be identified based on their frequency in fresh tumor\n\n\nCancer Immunol. Res., 4 (2016), pp. 734–743\n\n\n\n\nThis analysis of freshly resected metastatic melanomas showed that for 11/12 patient samples, the 5 most frequent TIL clonotypes comprised contained (up to 5) tumor-reactive TCRs, including neoantigen specificities. This result suggests that TIL TCR sequencing can identify tumor-reactive TCRs without knowledge of cognate epitopes, which is a potential strategy for developing TCR gene therapy for low mutational burden cancers.\n\n\n\n70\nM.R. Parkhurst, A. Gros, A. Pasetto, T.D. Prickett, J.S. Crystal, P.F. Robbins, S.A. Rosenberg\n\nIsolation of T cell receptors specifically reactive with mutated tumor associated antigens from tumor infiltrating lymphocytes based on CD137 expression\n\n\nClin. Cancer Res. (2016) https://doi.org/10.1158/1078-0432.CCR-16-2680 Advance online publication\n\n\n\n71\nC.M. Britten, H. Singh-Jasuja, B. Flamion, A. Hoos, C. Huber, K.J. Kallen, S.N. Khleif, S. Kreiter, M. Nielsen, H.G. Rammensee, et al.\n\nThe regulatory landscape for actively personalized cancer immunotherapies\n\n\nNat. Biotechnol., 31 (2013), pp. 880–882\n\n\n\n72\nS.L. Goff, F.O. Smith, J.A. Klapper, R. Sherry, J.R. Wunderlich, S.M. Steinberg, D. White, S.A. Rosenberg, M.E. Dudley, J.C. Yang\n\nTumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL\n\n\nJ. Immunother., 33 (2010), pp. 840–847\n\n\n\n73•\nE. Stronen, M. Toebes, S. Kelderman, M.M. van Buuren, W. Yang, N. van Rooij, M. Donia, M.L. Boschen, F. Lund-Johansen, J. Olweus, et al.\n\nTargeting of cancer neoantigens with donor-derived T cell receptor repertoires\n\n\nScience, 352 (2016), pp. 1337–1341\n\n\n\n\nThis study reports that naïve T cell repertoires of healthy blood donors react with 11/57 neoantigens identified from three patients with melanoma. By contrast, only 2 of these neoantigens elicited reactivity from autologous patient-derived TILs, suggesting unrelated donors may be a fecund source of neoantigen-reactive TCRs. An important caveat to this comparison is that healthy donor blood cells were expanded in the presence of these neoantigens prior to screening them whereas only TILs were tested from patients and no such expansion was performed.\n\n\n\n74\nG.P. Dunn, A.T. Bruce, H. Ikeda, L.J. Old, R.D. Schreiber\n\nCancer immunoediting: from immunosurveillance to tumor escape\n\n\nNat. Immunol., 3 (2002), pp. 991–998\n\n\n\n75\nC.S. Hinrichs, Z.A. Borman, L. Gattinoni, Z. Yu, W.R. Burns, J. Huang, C.A. Klebanoff, L.A. Johnson, S.P. Kerkar, S. Yang, et al.\n\nHuman effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy\n\n\nBlood, 117 (2011), pp. 808–814\n\n\n\n76\nL. Yang, D. Baltimore\n\nLong-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells\n\n\nProc. Natl. Acad. Sci. U. S. A., 102 (2005), pp. 4518–4523\n\n\n\n77\nB. Berdien, U. Mock, D. Atanackovic, B. Fehse\n\nTALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer\n\n\nGene Ther., 21 (2014), pp. 539–548\n\n\n\n78\nM. Bunse, G.M. Bendle, C. Linnemann, L. Bies, S. Schulz, T.N. Schumacher, W. Uckert\n\nRNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer\n\n\nMol. Ther., 22 (2014), pp. 1983–1991\n\n\n\n79\nS. Su, B. Hu, J. Shao, B. Shen, J. Du, Y. Du, J. Zhou, L. Yu, L. Zhang, F. Chen, et al.\n\nCRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients\n\n\nSci. Rep., 6 (2016), p. 20070\n\n\n\n80\nM.T. Bethune, M.H. Gee, M. Bunse, M.S. Lee, E.H. Gschweng, M.S. Pagadala, J. Zhou, D. Cheng, J.R. Heath, D.B. Kohn, et al.\n\nDomain-swapped T cell receptors improve the safety of TCR gene therapy\n\n\neLife (2016), p. 5\n\n\n\n81\nW. Qasim, H. Zhan, S. Samarasinghe, S. Adams, P. Amrolia, S. Stafford, K. Butler, C. Rivat, G. Wright, K. Somana, et al.\n\nMolecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells\n\n\nSci. Transl. Med., 9 (2017)\n\n\n\n82\nK.T. Roybal, L.J. Rupp, L. Morsut, W.J. Walker, K.A. McNally, J.S. Park, W.A. Lim\n\nPrecision tumor recognition by T cells with combinatorial antigen-sensing circuits\n\n\nCell, 164 (2016), pp. 770–779\n\n\n\n83\nE. Zah, M.Y. Lin, A. Silva-Benedict, M.C. Jensen, Y.Y. Chen\n\nT cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells\n\n\nCancer Immunol. Res., 4 (2016), pp. 498–508\n\n\n\n84\nK.T. Roybal, J.Z. Williams, L. Morsut, L.J. Rupp, I. Kolinko, J.H. Choe, W.J. Walker, K.A. McNally, W.A. Lim\n\nEngineering T cells with customized therapeutic response programs using synthetic notch receptors\n\n\nCell, 167 (2016) 419–432.e416\n\n\n\n\n85••\nL.B. Alexandrov, S. Nik-Zainal, D.C. Wedge, S.A. Aparicio, S. Behjati, A.V. Biankin, G.R. Bignell, N. Bolli, A. Borg, A.L. Borresen-Dale, et al.\n\nSignatures of mutational processes in human cancer\n\n\nNature, 500 (2013), pp. 415–421\n\n\n\n\nThis study illustrates the broad spectrum of mutational burdens within and between various human cancers. Taken together with the probabilistic relationship between mutation and neoantigen formation, expression, and T cell recognition, this result underscores the challenge of using mutational burden as a prognostic biomarker as well as the need for alternatives to exome-based antigen discovery methods for cancers with low mutational burden.\n\n\n\n86\nN. Sheikh, J. Cham, L. Zhang, T. DeVries, S. Letarte, J. Pufnock, D. Hamm, J. Trager, L. Fong\n\nClonotypic diversification of intratumoral T cells following sipuleucel-T treatment in prostate cancer subjects\n\n\nCancer Res., 76 (2016), pp. 3711–3718\n\n\n\n87\nW.C. Rutledge, J. Kong, J. Gao, D.A. Gutman, L.A. Cooper, C. Appin, Y. Park, L. Scarpace, T. Mikkelsen, M.L. Cohen, et al.\n\nTumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class\n\n\nClin. Cancer Res., 19 (2013), pp. 4951–4960\n\n\n\n88\nT.D. Prickett, J.S. Crystal, C.J. Cohen, A. Pasetto, M.R. Parkhurst, J.J. Gartner, X. Yao, R. Wang, A. Gros, Y.F. Li, et al.\n\nDurable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens\n\n\nCancer Immunol. Res., 4 (2016), pp. 669–678\n\n\n\n89\nA. Gros, P.F. Robbins, X. Yao, Y.F. Li, S. Turcotte, E. Tran, J.R. Wunderlich, A. Mixon, S. Farid, M.E. Dudley, et al.\n\nPD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors\n\n\nJ. Clin. Invest., 124 (2014), pp. 2246–2259\n\n\n\n90\nP.C. Tumeh, C.L. Harview, J.H. Yearley, I.P. Shintaku, E.J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, et al.\n\nPD-1 blockade induces responses by inhibiting adaptive immune resistance\n\n\nNature, 515 (2014), pp. 568–571\n\n\n\n91\nC. Linnemann, R. Mezzadra, T.N. Schumacher\n\nTCR repertoires of intratumoral T-cell subsets\n\n\nImmunol. Rev., 257 (2014), pp. 72–82\n\n\n\n92\nW.M. Hanson, Z. Chen, L.K. Jackson, M. Attaf, A.K. Sewell, J.M. Heemstra, J.D. Phillips\n\nReversible oligonucleotide chain blocking enables bead capture and amplification of T-cell receptor alpha and beta chain mRNAs\n\n\nJ. Am. Chem. Soc., 138 (2016), pp. 11073–11076\n\n\n\n93•\nB. Howie, A.M. Sherwood, A.D. Berkebile, J. Berka, R.O. Emerson, D.W. Williamson, I. Kirsch, M. Vignali, M.J. Rieder, C.S. Carlson, et al.\n\nHigh-throughput pairing of T cell receptor alpha and beta sequences\n\n\nSci. Transl. Med., 7 (2015), p. 301ra131\n\n\n\n\nThis study reports a technique for obtaining paired TCRα and TCRβ gene sequences in a high-throughput manner. This and other techniques will enable monitoring and discovery of TCRs involved in adaptive T cell responses to cancer (and in other pathologies) without the need to know the antigens targeted by that response.\n\n\n\n94\nBirnbaum ME, Mendoza JL, Bethune MT, Baltimore D, Garcia KC: Ligand discovery for T cell receptors. 2015, International Patent Application #WO/2015/153969.\n\n\n95\nJ.M. Zaretsky, A. Garcia-Diaz, D.S. Shin, H. Escuin-Ordinas, W. Hugo, S. Hu-Lieskovan, D.Y. Torrejon, G. Abril-Rodriguez, S. Sandoval, L. Barthly, et al.\n\nMutations associated with acquired resistance to PD-1 blockade in melanoma\n\n\nN. Engl. J. Med., 375 (2016), pp. 819–829\n\n\n"],"rights":"No commercial reproduction, distribution, display or performance rights in this work are provided.","official_citation":"Michael T Bethune, Alok V Joglekar, Personalized T cell-mediated cancer immunotherapy: progress and challenges, Current Opinion in Biotechnology, Volume 48, December 2017, Pages 142-152, ISSN 0958-1669, https://doi.org/10.1016/j.copbio.2017.03.024.\n(http://www.sciencedirect.com/science/article/pii/S095816691630283X)","other_numbering_system":null,"funders":[{"agency":"Prostate Cancer Foundation","grant_number":"15CHAL02"},{"agency":"Parker Institute for Cancer Immunotherapy","grant_number":""},{"agency":"Caltech Innovation Initiative (CI2)","grant_number":""},{"agency":"California Institute for Regenerative Medicine (CIRM)","grant_number":"DISC2-09123"}],"collection":"CaltechAUTHORS","reviewer":"GP","local_group":null}